Copy of Newspaper Publication
Q2FY27 results (unaudited):
Consolidated:
Revenue 41.7bn +33% y-y (31.4bn)
PAT 2.8bn n.a. (loss 1.0bn)
H1FY27 results (unaudited):
Consolidated:
Revenue 79.9bn +26% y-y (63.3bn)
PAT 4.5bn n.a. (0.4bn)
FY26 results (audited):
Consolidated:
Revenue 137bn n.a.
PAT (0.7bn) n.a.
Dividend: Interim dividend of 2.5 Rs/share declared
Commentary: The consolidated financial results for Q2 and H1 FY27 were reviewed by Deloitte Haskins & Sells LLP with an unmodified conclusion. The company raised Rs. 446.62 crores from a rights issue as of September 30, 2026, utilized as per the Letter of Offer.
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 SOLARA — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add SOLARA to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on Solara Active Pharma Sciences Limited
Important.
The summary above is generated automatically from Solara Active Pharma Sciences Limited's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.